Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis

Discussion When compared to single-gene DNA-based data alone, WGTA led to a 3-fold increase in treatment matching. In a setting where there is a high level of uncertainty around both the investigational agents and the biomarkers, more data are needed to fully evaluate the impact of routine use of WGTA.

Source: Investigational New Drugs - January 5, 2020 Category: Drugs & Pharmacology Source Type: research